Corbus Phamaceuticals

April 18, 2016April 19, 2016

FDA Approves Corbus Phase 2 Trial Extension of Systemic Sclerosis Drug Resunab

News, Scleroderma

Corbus Pharmaceuticals, a clinical stage company targeting rare, chronic inflammatory and fibrotic diseases, recently received approval by the U.S. Food and Drug Administration (FDA) for a 12-month open-label extension trial ... Read more

August 20, 2015November 6, 2015

Resunab Receives Fast Track FDA Status To Treat Scleroderma

News, Scleroderma

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development firm committed to addressing chronic, rare and serious inflammatory and fibrotic diseases, recently announced that the United States Food and Drug Administration (FDA) has ... Read more

June 15, 2015November 6, 2015

Corbus Announces FDA Orphan Drug Designation For Resunab To Address Systemic Sclerosis

News, Scleroderma

Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug advancement company focused on addressing chronic rare and serious fibrotic inflammatory diseases, announced recently that the United States Food and Drug Administration (FDA) has granted Corbus’ lead candidate ... Read more

April 27, 2015November 5, 2015

Corbus Pharmaceuticals Receives $5 Million Award From Cystic Fibrosis Foundation Therapeutics To Advance Resunab

Cystic Fibrosis, News

Corbus Pharmaceuticals Holdings, a clinical stage drug company developing therapies for rare, life-threatening inflammatory and fibrotic diseases, recently announced it has received a $5 million award from the Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT). ... Read more

March 11, 2015November 6, 2015

Corbus Pharmaceuticals’ IND Receives Clearance From FDA To Start Phase 2 Trials For Scleroderma

News, Scleroderma

Corbus Pharmaceuticals recently announced that the company’s Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) is now open and has received clearance to initiate a Phase 2 clinical ... Read more

February 13, 2015November 5, 2015

Corbus Releases 2014 Financial Results For CF, SSc Investigational Drug Development Efforts

Cystic Fibrosis

Emerging drug development company Corbus Pharmaceuticals Holding, Inc., which is currently working to commercialize therapeutic solutions for rare, life-threatening inflammatory and fibrotic diseases, recently presented its financial results for 2014. The company posted ... Read more

February 4, 2015November 6, 2015

Corbus Pharmaceuticals To Present on SSc, CF Therapy at 17th Annual BIO CEO & Investor Conference in February

News, Scleroderma

Corbus Pharmaceuticals Holdings, Inc., an emerging drug development company working on the advancement and marketing of its lead product candidate Resunab to address life-threatening and rare fibrotic and inflammatory diseases, announced recently that it ... Read more